Penumbra Q2 FY26 net income falls to 34.81 million; revenue rises 14.9% to 390 million

Operating income was $41 million; net income fell to $34.8 million, or $0.88 a share.

Gross margin widened 1.9 percentage points to 67.9%, while operating expenses climbed to $223.9 million, including $6.9 million in acquisition-related costs.

Penumbra withdrew full-year 2026 guidance and will not hold an earnings call due to its pending acquisition by Boston Scientific.

Penumbra reported Q2 revenue of $390 million, up 14.9% from a year earlier, led by embolization and access at $131.1 million, up 20%.

Thrombectomy revenue rose 12.5% to $259 million.